Gleevec/Glivec

Intellectual property threats in the BRIC markets

The recent upholding of the Indian patent office's rejection of Novartis' Glivec patent application is the latest in a series of actions including the compulsory licence of Nexavar and initiation

Ariad gets EU green light for leukaemia drug Iclusig

It can also be used in patients who are intolerant to Tasigna and Sprycel but are unsuitable for subsequent treatment with Novartis' Glivec (imatinib), as well as in CML patients who ... In the ALL indication, the Commission gave a green light for Iclusig

Merck wins injunction against Januvia generics in India

Earlier this year Novartis failed in a bid to secure protection for its Glivec (imatinib) cancer drug in India's Supreme Court, and there have also been knockbacks in recent months

Building BRICs: pharma's key emerging markets are becoming giants

In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court.

Payer focus in the personalised world of oncology and orphan diseases

more effective (eg Herceptin in HER2+ breast cancer, Iressa and Tarceva in EGFR mutation+ non-small cell lung cancer and Glivec in Philadelphia chromosome+ CML).

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]